FLT3 and acute myeloid leukemia: R/R AML tends to be more significantly driven by FLT3-ITD signaling and should benefit from more selective FLT3 inhibitors.143 While this is not totally confirmed in the clinic as of yet, current trials combining these various FLT3 inhibitors with induction chemotherapies in untreated AML may help answer this question.